Workflow
Pristinamycin
icon
Search documents
First-half 2025 results
Globenewswire· 2025-07-29 16:42
Press Release Paris, 29th July 2025 7% to 9% 2025 Core EBITDA margin guidance reaffirmed, with ambition to be in the upper part of the range, supported by thorough execution of the FOCUS-27 plan, and despite more challenging topline €412.1 million Net Sales (- 8.2% year-on-year) Challenging year-on-year comparison, primarily due to a €21 million one off in H1 2024, excluding this exceptional impact, sales would have declined by 4% EBITDA at €5.0 million compared to €(1.4) million in H1 2024 Core EBITDA at € ...